MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Industry news

News of the day

CML HealthCare Income Fund Reports 2009 Third Quarter Financial Results

MISSISSAUGA, ON, Nov. 11 - CML HealthCare Income Fund (the "Fund" or "CML HealthCare"), (TSX: CLC.UN) today reported its financial results for the three and nine-month periods ended September 30, 2009 (all amounts are in Canadian dollars, unless noted otherwise). more

Lonza successfully develops a manufacturing process for ArzerraTM (ofatumumab), a new biopharmaceutical from GSK and Genmab

Basel, Switzerland, 10 November 2009 - Lonza announces that GlaxoSmithKline (GSK) and Genmab's antibody ArzerraTM, which has just been approved for use in patients with chronic lymphocytic leukemia (CLL) by the US Food and Drug Administration (FDA), will be manufactured by Lonza. more

Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer

CAMBRIDGE, Mass. November 4, 2009 Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF superfamily from signaling through the activin receptor like kinase 1 (ALK1) receptor. The Phase 1 trial is a multiple... more

Industry news search

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
 
Category Therapeutic target
 
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Recent news

To keep up to date with news from this category use our RSS Feed to keep up to date

CML HealthCare Income Fund Announces Release Date for Fiscal 2009 Third Quarter Financial Results
MISSISSAUGA, ON, Nov. 4 - CML HealthCare Income Fund (TSX: CLC.UN), will release its 2009 third quarter financial results via www.newswire.ca prior to markets opening on November 11th , 2009. Following the release, CML...

ORTHO CLINICAL DIAGNOSTICS LAUNCHES FETALSCREEN(TM) II FETAL MATERNAL HEMORRHAGE SCREENING TEST
RARITAN, N.J. (Oct. 23, 2009) - Ortho Clinical Diagnostics announced the launch of FETALSCREEN(TM) II Fetal Maternal Hemorrhage Screening Test, a simple, qualitative test that detects D (Rho) positive fetal red blood...

Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems
MADISON, N.J., June 22, 2009 -- HemoCue Inc., the U.S. point-of-care testing distribution subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that it has signed an agreement with Medical Automation...

University of Southern California receives $1 million NIH grant to study TXA127 for the prevention of radiation damage
Brookline, MA, October 7,2008 -- Tarix Phamaceuticals today announced that the University of Southern California has received a grant to study the effects of TXA127 in preventing thrombocytopenia following radiation...

Tarix Pharmaceuticals receives FDA approval for Phase 2 study to mitigate chemotherapy-induced thrombocytopenia
Brookline,MA , June 25, 2008 -- Tarix Phamaceuticals announced that it has received FDA approval to begin a Phase II clinical trial of TXA127 for the prevention of chemotherapy induced thrombocytopenia. The trial will...

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us